Dhaka, Sept. 7 -- In what could prove to be a major breakthrough for cancer patients, an mRNA-based vaccine has been developed, demonstrating 100% efficacy and safety in clinical trials.

The Enteromix vaccine showed promising results during trials, helping patients with large tumors by significantly reducing their size and effectively destroying cancer cells, reports WION.

According to Russia Today (RT), the vaccine is now only awaiting final approval from the Russian Ministry of Health for public rollout.

Developed in Russia, Enteromix is the first cancer vaccine to utilize the same mRNA technology platform that was successfully used in COVID-19 vaccines.

This next-generation immunotherapy is designed to precisely target and eliminat...